Evidence map›Paper›PMID 39179685›Full record

ArticleCancer gene therapy2024

Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplification.

Christopher Zhang, Benson Z Wu, Caterina Di Ciano-Oliveira, Yin Fang Wu, Sharon S Khavkine Binstock, Isabel Soria-Bretones, Nhu-An Pham, Andrew J Elia, Raj Chari, Wan L Lam and 5 more

Abstract read
In one paragraph

Article in Cancer gene therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Christopher Zhang *Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Benson Z Wu *Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Caterina Di Ciano-OliveiraKeenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Toronto, Canada.
Yin Fang WuKeenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Toronto, Canada.
Sharon S Khavkine BinstockDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Isabel Soria-BretonesPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Nhu-An PhamPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Andrew J EliaPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Raj ChariLaboratory Animal Sciences Program, Genome Modification Core, Frederick National Laboratory for Cancer Research, Frederick, USA.
Wan L LamDepartment of Integrative Oncology, BC Cancer Research Institute, Vancouver, Canada.ORCID 0000-0002-0945-0644
Mark R BrayPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Tak W MakPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Ming-Sound TsaoDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.ORCID 0000-0002-9160-5405
David W CesconPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.ORCID 0000-0002-1080-0998
Kelsie L ThuDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada. kelsie.thu@unityhealth.to.ORCID 0000-0001-9262-7238

Funding

Canada Research Chairs (Chaires de recherche du Canada) 233198
6 · The paper itself

Abstract

Centrosome amplification (CA), an abnormal increase in the number of centrosomes in the cell, is a recurrent phenomenon in lung and other malignancies. Although CA promotes tumor development and progression by inducing genomic instability (GIN), it also induces mitotic stress that jeopardizes cellular integrity. CA leads to the formation of multipolar mitotic spindles that can cause lethal chromosome segregation errors. To sustain the benefits of CA by mitigating its consequences, malignant cells are dependent on adaptive mechanisms that represent therapeutic vulnerabilities. We aimed to discover genetic dependencies associated with CA in lung cancer. Combining a CRISPR/Cas9 functional genomics screen with tumor genomic analyses, we identified the motor protein KIFC1, also known as HSET, as a putative vulnerability specifically in lung adenocarcinoma (LUAD) with CA. KIFC1 expression was positively correlated with CA in LUAD and associated with worse patient outcomes, smoking history, and indicators of GIN. KIFC1 loss-of-function sensitized LUAD cells with high basal KIFC1 expression to potentiation of CA, which was associated with a diminished ability to cluster extra centrosomes into pseudo-bipolar mitotic spindles. Our work suggests that KIFC1 inhibition represents a novel approach for potentiating GIN to lethal levels in LUAD with CA by forcing cells to divide with multipolar spindles, rationalizing further studies to investigate its therapeutic potential.

Indexed as

CentrosomeKinesinsLung NeoplasmsAdenocarcinoma of LungCell Line, TumorHumansKIFC1 protein, humanKinesins

Identifiers

PMID39179685
PMCPMC11489082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.